S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.23
+1.55
+9.29%
PRAX · Praxis Precision Medicines, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Praxis Precision Medicines Inc (PRAX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$256.52
-8.08
(-3.05%)
● At close: October 21 at 4:00:00 PM EDT
$256.47
+0.00
(+0.00%)
Overnight:
2:44:07 AM EDT
DAY'S RANGE
$256.52
$256.20
$269.79
52-WEEK RANGE
$256.52
$154.45
$392.70
What's happening
- PRAX is down 3.05% today, trading at $256.52. — Live quote
- Volume today (26,386) is well below its 3-month average of 479,600. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-2.87 actual vs. $-3.73 estimated (+23.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 9
Buy 13
Hold 2
Sell 0
Strong sell 1
Aggregate ratings for 2026-10-01 (25 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
PRAX
-10.26%
vs S&P 500
-23.04%
1-YEAR RETURN
PRAX
+51.08%
vs S&P 500
+36.52%
6-MONTH RETURN
PRAX
-17.45%
3-MONTH RETURN
PRAX
-16.79%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-2.87
Est. $-3.73
BEAT +23.1%
2026-04-26 (Q1 2026)
$-3.20
Est. $-3.58
BEAT +10.7%
2026-01-26 (Q4 2025)
$-3.50
Est. $-3.16
MISS -10.7%
2025-10-26 (Q3 2025)
$-3.36
Est. $-3.51
BEAT +4.3%
Valuation Measures & Ratios
Enterprise Value4$6.91B
Forward P/E5—
PEG Ratio6-3.78
Price / Sales (TTM1)863.39
Price / Book76.96
EV4 / Revenue807.88
EV4 / EBITDA—
Profit Margin-2137.48%
Operating Margin-2340.29%
Return on Equity (ROE8)-43.02%
Return on Assets (ROA9)-40.22%
Avg Volume (3M)479,600
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $9.78B | $9.32B | $1.17B | $906.8M | $798.6M |
| P/E | -30.44 | -30.35 | -4.27 | -3.61 | -3.76 |
| Price/Book | 7.29 | 6.61 | 3.40 | 2.24 | 1.82 |
| ROE | -23.96% | -21.77% | -79.49% | -62.10% | -48.40% |
| ROA | -23.12% | -21.02% | -68.88% | -55.43% | -44.40% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short4,188,193
Change from Prior Settlement+10.34%
% of Float—
Days to Cover (Short Ratio)7.16
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +51.1%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -2137.5%. Finnhub fundamentals ↗
- Latest SEC filing is Form 10-Q, filed 2026-08-06; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PRAX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | — | $302.0K | $357.0K |
| Operating income | -$96.9M | -$105.9M | -$78.4M | -$76.1M | -$74.7M | — | -$56.8M | -$37.5M |
| Net income | -$83.7M | -$92.6M | -$73.9M | -$71.1M | -$69.3M | -$58.7M | -$51.9M | -$32.7M |
| EPS (diluted) | $-2.87 | $-3.20 | $-3.36 | $-3.31 | $-3.29 | — | $-2.75 | $-1.74 |
| EPS (basic) | $-2.87 | $-3.20 | $-3.36 | $-3.31 | $-3.29 | — | $-2.75 | $-1.74 |
| Operating margin | — | — | — | — | — | — | -$18.8K | -$10.5K |
| Net margin | — | — | — | — | — | — | -$17.2K | -$9.2K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.39B | $1.46B | $937.9M | $396.4M | $452.8M | $478.7M | $483.1M | $416.3M |
| Total liabilities | $49.1M | $50.2M | $59.8M | $52.9M | $48.6M | $39.5M | $37.7M | $33.6M |
| Stockholders' equity | $1.34B | $1.41B | $878.1M | $343.5M | $404.2M | $439.2M | $445.4M | $382.7M |
| Total current assets | $771.9M | $797.8M | $610.9M | $273.8M | $306.6M | $333.6M | $404.4M | $360.0M |
| Total current liabilities | $49.1M | $50.2M | $59.8M | $52.9M | $48.6M | $39.5M | $37.5M | $32.9M |
| Cash & equivalents | $474.8M | $536.3M | $357.3M | $149.5M | $157.4M | $165.6M | $215.4M | $168.6M |
| Marketable securities (current) | $283.8M | $250.5M | $242.0M | — | — | — | $177.2M | — |
| Marketable securities (non-current) | $615.3M | $660.9M | $326.8M | — | — | — | $77.0M | — |
| Property, plant & equipment | $492.0K | $170.0K | $147.0K | $174.0K | $258.0K | $247.0K | $230.0K | $277.0K |
| Intangible assets | $773.0K | — | $0 | — | — | — | — | — |
| Other non-current assets | $643.0K | — | $0 | $0 | $0 | $0 | $416.0K | $416.0K |
| Accounts payable | $23.4M | $31.2M | $24.6M | $30.8M | $28.8M | $22.9M | $12.5M | $15.0M |
| Accrued liabilities | $24.6M | $17.6M | $35.0M | $21.6M | $19.0M | $15.5M | $23.8M | $15.5M |
| Deferred revenue (current) | — | — | — | — | — | — | $0 | $1.2M |
| Common stock & paid-in capital | $15.0K | $15.0K | $15.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K |
| Retained earnings | -$1.32B | -$1.23B | -$1.14B | -$1.05B | -$977.2M | -$906.0M | -$836.7M | -$778.1M |
| Accumulated other comprehensive income (loss) | -$2.7M | -$1.6M | $563.0K | $500.0K | $395.0K | $659.0K | $654.0K | $1.3M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$77.5M | -$86.2M | -$76.3M | -$65.1M | -$54.7M | -$53.0M | -$56.1M | -$27.5M |
| Investing cash flow | $11.0M | -$344.3M | -$328.4M | $50.4M | $17.9M | -$51.1M | -$10.9M | $49.6M |
| Financing cash flow | $4.6M | $609.4M | $612.5M | $6.8M | $28.6M | $54.3M | $113.8M | $1.4M |
| Free cash flow | -$77.8M | -$86.2M | -$76.3M | -$65.1M | -$54.7M | -$53.0M | -$56.1M | -$27.5M |
| Capital expenditures | $245.0K | $62.0K | $0 | $0 | $56.0K | $0 | $0 | $0 |
| Share-based compensation | $11.3M | $17.1M | $9.9M | $7.4M | $7.8M | $8.8M | $8.6M | $12.4M |
| Change in accounts payable | -$7.9M | $6.5M | -$6.2M | $2.0M | $5.9M | $10.4M | -$2.5M | $7.0M |
| Purchases of investments | $77.3M | $486.8M | $390.3M | $75.1M | $41.3M | $117.1M | $69.4M | $12.0M |
| Tax withholding on stock comp | $310.0K | $12.9M | $819.0K | $52.0K | $23.0K | $1.2M | $157.0K | $1.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $8.6M | $2.4M | $0 | — |
| Operating income | -$326.2M | -$200.2M | -$126.4M | -$215.0M | -$167.3M |
| Net income | -$303.3M | -$182.8M | -$123.3M | -$214.0M | -$167.1M |
| EPS (diluted) | $-13.48 | $-10.21 | $-18.69 | $-69.65 | $-3.94 |
| EPS (basic) | $-13.48 | $-10.21 | $-18.69 | $-69.65 | $-3.94 |
| Operating margin | — | -$2.3K | -$5.2K | — | — |
| Net margin | — | -$2.1K | -$5.0K | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|
| Total assets | $937.9M | $483.1M | — | — | — |
| Total liabilities | $59.8M | $37.7M | — | — | — |
| Stockholders' equity | $878.1M | $445.4M | $382.7M | $419.1M | $229.7M |
| Total current assets | $610.9M | $404.4M | — | — | — |
| Total current liabilities | $59.8M | $37.5M | — | — | — |
| Cash & equivalents | $357.3M | $215.4M | — | — | — |
| Marketable securities (current) | $242.0M | $177.2M | — | — | — |
| Marketable securities (non-current) | $326.8M | $77.0M | — | — | — |
| Property, plant & equipment | $147.0K | $230.0K | — | — | — |
| Other non-current assets | $0 | $416.0K | — | — | — |
| Accounts payable | $24.6M | $12.5M | — | — | — |
| Accrued liabilities | $35.0M | $23.8M | — | — | — |
| Deferred revenue (current) | — | $0 | — | — | — |
| Common stock & paid-in capital | $15.0K | $14.0K | — | — | — |
| Retained earnings | -$1.14B | -$836.7M | — | — | — |
| Accumulated other comprehensive income (loss) | $563.0K | $654.0K | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$249.1M | -$131.8M | -$111.1M | -$185.0M | -$124.6M |
| Investing cash flow | -$311.1M | -$248.5M | $39.0M | $96.9M | -$140.5M |
| Financing cash flow | $702.2M | $514.3M | $91.9M | $10.5M | $107.6M |
| Free cash flow | -$249.1M | -$131.8M | -$111.2M | -$185.5M | -$125.6M |
| Capital expenditures | $56.0K | $0 | $50.0K | $444.0K | $1.1M |
| Share-based compensation | $33.9M | $41.4M | $24.9M | $28.6M | $22.7M |
| Change in accounts payable | $12.1M | $6.7M | -$8.9M | $3.9M | $7.3M |
| Purchases of investments | $623.8M | $371.5M | $0 | $83.0M | $164.2M |
| Tax withholding on stock comp | $2.1M | $308.0K | $137.0K | $260.0K | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PRAX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-01-08 to 2026-07-08
Recent transactions
- Insiders have net sold 11,600 shares over the last 182 days, across 0 purchases and 12 sales.
- Most recent: Souza Marcio (Chief Executive Officer) — Gift of 20,521 shares on 2026-07-08.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)11,600 sh(12 txns)
Net Shares-11,600
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Souza Marcio | Chief Executive Officer | Gift | 2026-07-08 | 20,521 |
| DeSimone Jill | Director | Option exercise | 2026-06-24 | 8,566 |
| Arbuckle Stuart A | Director | Grant / award | 2026-06-10 | 1,371 |
| Chodakewitz Jeffrey | Director | Grant / award | 2026-06-10 | 1,371 |
| YOUNG WILLIAM D | Director | Grant / award | 2026-06-10 | 1,371 |
| Cudkowicz Merit Ester | Director | Grant / award | 2026-06-10 | 1,371 |
| MITCHELL DEAN J | Director | Grant / award | 2026-06-10 | 1,371 |
| KINDLER JEFFREY B | Director | Grant / award | 2026-06-10 | 1,371 |
| Norden Gregory | Director | Grant / award | 2026-06-10 | 1,371 |
| Mastrocola Lauren | Principal Accounting Officer | Grant / award | 2026-05-14 | 127 |
| Nemiroff Alex | General Counsel and Secretary | Grant / award | 2026-05-14 | 78 |
| Kelly Timothy Edwin | Chief Financial Officer | Grant / award | 2026-05-14 | 121 |
| Sniecinski Megan | Chief Operating Officer | Grant / award | 2026-05-14 | 89 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-08 | Souza Marcio | Chief Executive Officer | Gift | 20,521 | $0.00 |
| 2026-07-08 | Souza Marcio | Chief Executive Officer | Gift | 2,600 | $0.00 |
| 2026-06-24 | DeSimone Jill | Director | Option exercise | 8,566 | $44.25 |
| 2026-06-24 | DeSimone Jill | Director | Option exercise | 3,034 | $147.30 |
| 2026-06-24 | DeSimone Jill | Director | Open market sale | 10 | $301.44 |
| 2026-06-24 | DeSimone Jill | Director | Open market sale | 120 | $303.13 |
| 2026-06-24 | DeSimone Jill | Director | Open market sale | 320 | $305.31 |
| 2026-06-24 | DeSimone Jill | Director | Open market sale | 683 | $306.77 |
| 2026-06-24 | DeSimone Jill | Director | Open market sale | 1,240 | $308.24 |
| 2026-06-24 | DeSimone Jill | Director | Open market sale | 999 | $309.38 |
| 2026-06-24 | DeSimone Jill | Director | Open market sale | 1,750 | $310.89 |
| 2026-06-24 | DeSimone Jill | Director | Open market sale | 2,854 | $311.91 |
| 2026-06-24 | DeSimone Jill | Director | Open market sale | 1,004 | $312.83 |
| 2026-06-24 | DeSimone Jill | Director | Open market sale | 504 | $313.66 |
| 2026-06-24 | DeSimone Jill | Director | Open market sale | 1,279 | $314.90 |
| 2026-06-24 | DeSimone Jill | Director | Open market sale | 837 | $315.70 |
| 2026-06-10 | Arbuckle Stuart A | Director | Grant / award | 1,371 | $0.00 |
| 2026-06-10 | Chodakewitz Jeffrey | Director | Grant / award | 1,371 | $0.00 |
| 2026-06-10 | YOUNG WILLIAM D | Director | Grant / award | 1,371 | $0.00 |
| 2026-06-10 | DeSimone Jill | Director | Grant / award | 1,371 | $0.00 |
| 2026-06-10 | Cudkowicz Merit Ester | Director | Grant / award | 1,371 | $0.00 |
| 2026-06-10 | MITCHELL DEAN J | Director | Grant / award | 1,371 | $0.00 |
| 2026-06-10 | KINDLER JEFFREY B | Director | Grant / award | 1,371 | $0.00 |
| 2026-06-10 | Norden Gregory | Director | Grant / award | 1,371 | $0.00 |
| 2026-05-14 | Mastrocola Lauren | Principal Accounting Officer | Grant / award | 127 | $167.94 |
| 2026-05-14 | Nemiroff Alex | General Counsel and Secretary | Grant / award | 78 | $167.94 |
| 2026-05-14 | Kelly Timothy Edwin | Chief Financial Officer | Grant / award | 121 | $167.94 |
| 2026-05-14 | Sniecinski Megan | Chief Operating Officer | Grant / award | 89 | $167.94 |
| 2026-05-14 | Souza Marcio | Chief Executive Officer | Grant / award | 126 | $167.94 |
| 2026-02-06 | Arbuckle Stuart A | Director | Grant / award | 688 | $0.00 |
| 2026-02-06 | Arbuckle Stuart A | Director | Grant / award | 478 | $0.00 |
| 2026-02-06 | KINDLER JEFFREY B | Director | Grant / award | 688 | $0.00 |
| 2026-02-06 | KINDLER JEFFREY B | Director | Grant / award | 478 | $0.00 |
| 2026-01-12 | Mastrocola Lauren | Principal Accounting Officer | Tax withholding | 344 | $275.74 |
| 2026-01-12 | Sniecinski Megan | Chief Operating Officer | Tax withholding | 885 | $275.74 |
| 2026-01-12 | Nemiroff Alex | General Counsel and Secretary | Tax withholding | 768 | $275.74 |
| 2026-01-12 | Kelly Timothy Edwin | Chief Financial Officer | Tax withholding | 943 | $275.74 |
| 2026-01-10 | Mastrocola Lauren | Principal Accounting Officer | Tax withholding | 367 | $288.45 |
| 2026-01-10 | Sniecinski Megan | Chief Operating Officer | Tax withholding | 1,087 | $288.45 |
| 2026-01-10 | Nemiroff Alex | General Counsel and Secretary | Tax withholding | 917 | $288.45 |
| 2026-01-10 | Kelly Timothy Edwin | Chief Financial Officer | Tax withholding | 1,335 | $288.45 |
| 2026-01-08 | Mastrocola Lauren | Principal Accounting Officer | Grant / award | 3,750 | $0.00 |
| 2026-01-08 | Sniecinski Megan | Chief Operating Officer | Grant / award | 9,625 | $0.00 |
| 2026-01-08 | Nemiroff Alex | General Counsel and Secretary | Grant / award | 6,875 | $0.00 |
| 2026-01-08 | Kelly Timothy Edwin | Chief Financial Officer | Grant / award | 8,800 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:48 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-08 | View on SEC.gov → |
| 2026-07-07 | 8-K | 2026-07-07 | View on SEC.gov → |
| 2026-07-02 | 8-K | 2026-06-29 | View on SEC.gov → |
| 2026-06-29 | 8-K | 2026-06-29 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-22 | 8-K | 2026-06-22 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-10 | View on SEC.gov → |
Recent news
Headlines about PRAX (Praxis Precision Medicines, Inc.). Links open the publisher — we don’t host full articles.
-
PRAX280317C00320000 Interactive Stock Chart | PRAX Mar 2028 320.000 call Stock
Yahoo Finance · 2026-10-21 -
PRAX Mar 2028 320.000 call (PRAX280317C00320000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21 -
PRAX Nov 2026 250.000 call (PRAX261120C00250000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
Praxis Precision Medicines Rises as Investors Revisit Late-2026 FDA Catalysts
Quiver Quantitative · 2026-10-19 -
Is Praxis Precision Medicines (PRAX) Priced Too Highly On Book Value?
Yahoo Finance · 2026-10-18 -
Praxis Stock Slides As Optimism Meets Harsh Reality
TipRanks · 2026-10-16 -
PRAX Initiated Coverage by JP Morgan -- Rating Set to Overweight
GuruFocus · 2026-10-16 -
Workday downgraded, Fox Corp. upgraded: Wall Street's top analyst calls
Yahoo Finance · 2026-10-16
No headlines in this category right now — try “All”.